Uncategorized
Omeros completes enrollment in pediatric clinical trial of Omidria
Omeros has completed patient enrollment in a post-marketing pediatric clinical trial of Omidria, according to a press release. As an FDA post-marketing requirement, the company has enrolled 70 cataract surgery patients between 0 and 3 years of age. Upon successful completion of the clinical trial, Omeros will be eligible to receive an additional 6 months of marketing exclusivity for Omidria (phenylephrine 1% and ketorolac 0.3% injection).